Vitrolife AB (publ) (LON: 0YAY)
London
· Delayed Price · Currency is GBP · Price in SEK 222.00
-12.60 (-5.37%)
At close: Jan 31, 2025
Vitrolife AB Revenue
In the year 2024, Vitrolife AB had annual revenue of 3.61B SEK with 2.76% growth. Vitrolife AB had revenue of 959.00M in the quarter ending December 31, 2024, with 5.97% growth.
Revenue
3.61B SEK
Revenue Growth
+2.76%
P/S Ratio
n/a
Revenue / Employee
3.21M SEK
Employees
1,123
Market Cap
2.20B GBP
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.61B | 97.00M | 2.76% |
| Dec 31, 2023 | 3.51B | 278.00M | 8.60% |
| Dec 31, 2022 | 3.23B | 1.55B | 92.39% |
| Dec 31, 2021 | 1.68B | 435.43M | 34.96% |
| Dec 31, 2020 | 1.25B | -234.56M | -15.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 38.20B |
| GSK plc | 31.31B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| ConvaTec Group | 1.74B |
| Hikma Pharmaceuticals | 2.39B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |